Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

OBJECTIVES: To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the initial therapy. METHODS: SELECT-COMPARE randomised patients to upadacitinib 15 mg once daily (n=651),...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Fleischmann, Roy M, Blanco, Ricardo, Hall, Stephen, Thomson, Glen T D, Van den Bosch, Filip E, Zerbini, Cristiano, Bessette, Louis, Enejosa, Jeffrey, Li, Yihan, Song, Yanna, DeMasi, Ryan, Song, In-Ho
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958110/
https://ncbi.nlm.nih.gov/pubmed/33148701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-218412
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados